Many small molecule kinase inhibitors (SMKIs) used to combat most cancers have been related to cardiotoxicity within the clinic. Due to this fact, stopping their failure in scientific improvement is a precedence for preclinical discovery. Our examine targeted on the mixing and concurrent measurement of ATP, apoptosis dynamics and practical cardiac indexes in human stem cell-derived cardiomyocytes (hSC-CMs) to offer additional insights into molecular determinants of compromised cardiac operate.
Ten out of the fourteen examined SMKIs resulted in a biologically related lower in both beating price or base impedance (cell quantity index), illustrating cardiotoxicity as one of many main security liabilities of SMKIs, specifically of these concerned within the PI3K-AKT pathway. Pearson’s correlation evaluation indicated correlation between the totally different read-outs of practical significance. Due to this fact, measurement of ATP concentrations and apoptosis in vitro may present essential perception into mechanisms of cardiotoxicity.
Detailed investigation of the mobile indicators facilitated multi-parameter analysis permitting integrative evaluation of cardiomyocyte conduct. The ensuing correlation can be utilized as a device to focus on adjustments in cardiac operate and doubtlessly to categorize medication primarily based on their mechanisms of motion. The commonest sort of spinal twine harm is the contusion of the spinal twine, which causes progressive secondary tissue degeneration. On this examine, we utilized genetically modified human neural stem cells overexpressing BDNF (brain-derived neurotrophic issue) (F3.BDNF) to find out whether or not they can promote practical restoration within the spinal twine harm (SCI) mannequin in rats.
We transplanted F3.BDNF cells by way of intrathecal catheter supply after a contusion of the thoracic spinal twine and located that they have been migrated towards the injured spinal twine space by MR imaging. Transplanted F3.BDNF cells expressed neural lineage markers, akin to NeuN, MBP, and GFAP and have been functionally related to the host neurons. The F3.BDNF-transplanted rats exhibited considerably improved locomotor features in contrast with the sham group. This practical restoration was accompanied by an elevated quantity of spared myelination and decreased space of cystic cavity within the F3.BDNF group.
Human Induced Pluripotent Stem Cell-Derived Neural Progenitor Cells Produce Distinct Neural 3D In Vitro Fashions Relying on Alginate/Gellan Gum/Laminin Hydrogel Mix Properties
Secure and predictive neural cell tradition fashions are a essential premise for a lot of analysis fields. Nevertheless, standard 2D fashions lack 3D cell-material/-cell interactions and therefore don’t replicate the complexity of the in vivo state of affairs correctly. Right here two alginate/gellan gum/laminin (ALG/GG/LAM) hydrogel blends are offered for the fabrication of human induced pluripotent stem cell (hiPSC)-based 3D neural fashions. For hydrogel embedding, hiPSC-derived neural progenitor cells (hiNPCs) are used both straight or after 3D neural pre-differentiation. It’s proven that stiffness and stress leisure of the gel blends, in addition to the cell differentiation technique affect 3D mannequin improvement.
The embedded hiNPCs differentiate into neurons and astrocytes throughout the gel blends and show spontaneous intracellular calcium indicators. Two fit-for-purpose fashions worthwhile for i) purposes requiring a excessive diploma of complexity, however much less throughput, akin to illness modeling and long-term publicity research and ii) larger throughput purposes, akin to acute exposures or substance screenings are proposed. Resulting from their big selection of purposes, adjustability, and printing capabilities, the ALG/GG/LAM primarily based 3D neural fashions are of nice potential for 3D neural modeling sooner or later. Chromosomal translocations represent driver mutations in stable tumors and leukemias.
The mechanisms of how associated and even an identical gene fusions drive the pathogenesis of assorted tumor sorts stay elusive. One exceptional instance is the presence of EWSR1 fusions with CREB1 and ATF1, members of the CREB household of transcription elements, in quite a lot of sarcomas, carcinomas and mesotheliomas. To handle this, we have now developed in vitro fashions of oncogenic fusions, specifically, EWSR1-CREB1 and EWSR1-ATF1, in human embryonic stem (hES) cells, that are able to multipotent differentiation, utilizing CRISPR-Cas9 expertise and HDR along with conditional fusion gene expression that enables investigation into the early steps of mobile transformation.

Transcriptomic adjustments upon epoxiconazole publicity in a human stem cell-based mannequin of developmental toxicity
Conazole fungicides akin to epoxiconazole are principally used on cereals of crops to inhibit fungal progress via direct inhibition of sterol 14α-demethylase (CYP51A1). Nevertheless, this enzyme is extremely conserved and in people it’s a part of the steroid hormone biosynthesis pathway. Endocrine disrupting results of epoxiconazole have been proven in rodents and have been substantiated by in vitro information, nonetheless, the underlying molecular mechanisms aren’t clear. We took benefit of a human stem cell primarily based in vitro mannequin for developmental toxicity to review the molecular results of epoxiconazole.
This mannequin is predicated on 3D cultures of embryoid our bodies and differentiation into cardiomyocytes, which mimics the early phases of embryonic improvement. Now we have beforehand proven that epoxiconazole impairs differentiation of those embryoid our bodies and due to this fact has the potential to have an effect on human embryonic improvement. We employed world transcriptome evaluation utilizing RNA sequencing and located that the steroid biosynthesis pathway together with CYP51A1, the human sterol 14α-demethylase, was extremely deregulated by epoxiconazole in our mannequin. We confirmed that almost all genes of the steroid biosynthesis pathway have been upregulated, together with CYP51A1, suggesting a compensatory mechanism on the gene expression degree.
SCL-70 Antigen |
|
MBS569401-5x1mg |
MyBiosource |
5x1mg |
EUR 7395 |
Cow Scl-70 Antigen |
|
abx069937-10g |
Abbexa |
10 g |
Ask for price |
Cow Scl-70 Antigen |
|
abx069937-5g |
Abbexa |
5 g |
EUR 1750 |
Rabbit Scl-70 Antigen |
|
abx069936-25g |
Abbexa |
25 g |
EUR 1862.5 |
Scl-70 Antigen Antibody |
|
abx022697-2ml |
Abbexa |
2 ml |
EUR 594 |
|
|
Scl-70 Antigen Antibody |
|
abx022697-400l |
Abbexa |
400 µl |
Ask for price |
Scl-70 Antigen Antibody |
|
abx022697-80l |
Abbexa |
80 µl |
EUR 575 |
Scl-70 Antigen Protein |
|
abx069936-1000Units |
Abbexa |
1000 Units |
EUR 1846.8 |
|
|
Scl-70 Antigen Protein |
|
abx069937-02mg |
Abbexa |
0.2 mg |
EUR 1296 |
|
|
Borrelia Afzelii Antigen |
|
NAT41583-100 |
The Native Antigen Company |
0.1 |
EUR 395.28 |
|
|
|
Description: Harvested bacteria are washed and detergent solubilized to produce a cytoplasmic extract enriched with lipoproteins and outer surface proteins (OSPs). The antigen is presented in phosphate buffered saline containing 1 % n-octyl-β-D-glucopyranoside. |
Borrelia Afzelii Antigen |
|
NAT41583-500 |
The Native Antigen Company |
0.5 |
EUR 1187.13 |
|
|
|
Description: Harvested bacteria are washed and detergent solubilized to produce a cytoplasmic extract enriched with lipoproteins and outer surface proteins (OSPs). The antigen is presented in phosphate buffered saline containing 1 % n-octyl-β-D-glucopyranoside. |
Borrelia Garinii Antigen |
|
NAT41584-100 |
The Native Antigen Company |
0.1 |
EUR 395.28 |
|
|
|
Description: Harvested bacteria are washed and detergent solubilized to produce a cytoplasmic extract enriched with lipoproteins and outer surface proteins (OSPs). The antigen is presented in phosphate buffered saline containing 1 % n-octyl-β-D-glucopyranoside. |
Borrelia Garinii Antigen |
|
NAT41584-500 |
The Native Antigen Company |
0.5 |
EUR 1187.13 |
|
|
|
Description: Harvested bacteria are washed and detergent solubilized to produce a cytoplasmic extract enriched with lipoproteins and outer surface proteins (OSPs). The antigen is presented in phosphate buffered saline containing 1 % n-octyl-β-D-glucopyranoside. |
Brucella Abortus Antigen |
|
NAT41599-100 |
The Native Antigen Company |
0.1 |
EUR 395.28 |
|
|
|
Description: Brucella abortus lysate, produced by fermentation. |
Brucella Abortus Antigen |
|
NAT41599-500 |
The Native Antigen Company |
0.5 |
EUR 1187.13 |
|
|
|
Description: Brucella abortus lysate, produced by fermentation. |
Candida Albicans Antigen |
|
NAT41601-100 |
The Native Antigen Company |
0.1 |
EUR 395.28 |
|
|
|
Description: Candida albicans is grown on solid medium, washed, disrupted and subjected to an extraction process. The antigen consists of cytoplasmic and cell wall components. |
Candida Albicans Antigen |
|
NAT41601-500 |
The Native Antigen Company |
0.5 |
EUR 1187.13 |
|
|
|
Description: Candida albicans is grown on solid medium, washed, disrupted and subjected to an extraction process. The antigen consists of cytoplasmic and cell wall components. |
Canine Parvovirus Antigen |
|
NAT41594-100 |
The Native Antigen Company |
0.1 |
EUR 395.28 |
|
|
|
Description: Canine Parvovirus, produced in CRFK cells. |
Canine Coronavirus Antigen |
|
NAT41590-100 |
The Native Antigen Company |
0.1 |
EUR 395.28 |
|
|
|
Description: Canine Coronavirus produced in A-72 cells. |
Feline Calicivirus Antigen |
|
NAT41595-100 |
The Native Antigen Company |
0.1 |
EUR 395.28 |
|
|
|
Description: Feline Calicivirus produced in FC 3TG cells. |
Helicobacter Pylori Antigen |
|
NAT41603-100 |
The Native Antigen Company |
0.1 |
EUR 395.28 |
|
|
|
Description: Bacteria are cultured on solid medium, harvested, washed and solubilised. The antigen is partially purified by detergent extraction and centrifugation. |
Helicobacter Pylori Antigen |
|
NAT41603-500 |
The Native Antigen Company |
0.5 |
EUR 1187.13 |
|
|
|
Description: Bacteria are cultured on solid medium, harvested, washed and solubilised. The antigen is partially purified by detergent extraction and centrifugation. |
Campylobacter Jejuni Antigen |
|
NAT41600-100 |
The Native Antigen Company |
0.1 |
EUR 395.28 |
|
|
|
Description: Campylobacter jejuni is cultured on solid medium. This antigen is a partially purified detergent extract of the membrane fraction. The main component is an outer membrane protein, approximately 45 kDa in SDS-PAGE. |
Campylobacter Jejuni Antigen |
|
NAT41600-500 |
The Native Antigen Company |
0.5 |
EUR 1187.13 |
|
|
|
Description: Campylobacter jejuni is cultured on solid medium. This antigen is a partially purified detergent extract of the membrane fraction. The main component is an outer membrane protein, approximately 45 kDa in SDS-PAGE. |
Chlamydia Trachomatis Antigen |
|
CT022-1000 |
The Native Antigen Company |
1.0 |
EUR 382.41 |
|
|
|
Description: Chlamydia trachomatis antigens from clarified cell lysate. |
Mycoplasma Pneumoniae Antigen |
|
MP901-1000 |
The Native Antigen Company |
1.0 |
EUR 1019.75 |
|
|
|
Description: Mycoplasma pneumoniae whole organisms that have been purified and detergent treated to enrich antigenic proteins and decrease background. |
Mycoplasma Pneumoniae Antigen |
|
MP901-200 |
The Native Antigen Company |
0.2 |
EUR 272.96 |
|
|
|
Description: Mycoplasma pneumoniae whole organisms that have been purified and detergent treated to enrich antigenic proteins and decrease background. |
Neisseria Gonorrhoeae Antigen |
|
NG01-1000 |
The Native Antigen Company |
1.0 |
EUR 382.41 |
|
Description: Homogenised lysate of pure bacteria. |
Echovirus Antigen, Recombinant |
|
REC31776-100 |
The Native Antigen Company |
0.1 |
EUR 279.4 |
|
|
|
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus |
Echovirus Antigen, Recombinant |
|
REC31776-500 |
The Native Antigen Company |
0.5 |
EUR 1053.23 |
|
|
|
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus |
Trichomonas Vaginalis Antigen |
|
TV01-1000 |
The Native Antigen Company |
1.0 |
EUR 424.9 |
|
|
|
Description: Washed & lysed suspension of whole protozoa |
Scl-70 |
|
MBS634416-1000Units |
MyBiosource |
1000Units |
EUR 1735 |
Scl-70 |
|
MBS634416-5x1000Units |
MyBiosource |
5x1000Units |
EUR 7580 |
Echinococcus Granulosus Antigen |
|
NAT41602-100 |
The Native Antigen Company |
0.1 |
EUR 395.28 |
|
|
|
Description: Echinococcus granulosus material is derived from bovine hydatid cyst as sterile filtered cyst fluid. |
Echinococcus Granulosus Antigen |
|
NAT41602-500 |
The Native Antigen Company |
0.5 |
EUR 1187.13 |
|
|
|
Description: Echinococcus granulosus material is derived from bovine hydatid cyst as sterile filtered cyst fluid. |
Enterovirus Antigen, Recombinant |
|
REC31772-100 |
The Native Antigen Company |
0.1 |
EUR 279.4 |
|
|
|
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus IgA, IgG and IgM ELISA. |
Enterovirus Antigen, Recombinant |
|
REC31772-500 |
The Native Antigen Company |
0.5 |
EUR 1053.23 |
|
|
|
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus IgA, IgG and IgM ELISA. |
Cytomegalovirus Purified Antigen |
|
CMV-HP-100 |
The Native Antigen Company |
0.1 |
EUR 321.89 |
|
|
|
Description: A concentrated source of human Cytomegalovirus particles purified by sucrose gradient ultracentrifugation. |
Cytomegalovirus Purified Antigen |
|
CMV-HP-1000 |
The Native Antigen Company |
1.0 |
EUR 2115.47 |
|
|
|
Description: A concentrated source of human Cytomegalovirus particles purified by sucrose gradient ultracentrifugation. |
Cytomegalovirus Purified Antigen |
|
CMV-HP-500 |
The Native Antigen Company |
0.5 |
EUR 1291.43 |
|
|
|
Description: A concentrated source of human Cytomegalovirus particles purified by sucrose gradient ultracentrifugation. |
Astrovirus Antigen (Type 1) |
|
AS02-1000 |
The Native Antigen Company |
1.0 |
EUR 1669.97 |
|
|
|
Description: A concentrated source of Astrovirus particles and Astrovirus proteins from a lysate of host cells. |
Astrovirus Antigen (Type 1) |
|
AS02-200 |
The Native Antigen Company |
0.2 |
EUR 446.78 |
|
|
|
Description: A concentrated source of Astrovirus particles and Astrovirus proteins from a lysate of host cells. |
Yersinia pestis V antigen |
|
REC32028-100 |
The Native Antigen Company |
0.1 |
EUR 326.34 |
|
Description: Yersinia pestis V antigen (LcrV antigen, capsule protein fraction 1, type III secretion system needle tip protein). The protein is produced as an N-terminal GST fusion, with GST being cleaved by thrombin and is not present in the final product. |
Yersinia pestis V antigen |
|
REC32028-500 |
The Native Antigen Company |
0.5 |
EUR 1386.95 |
|
Description: Yersinia pestis V antigen (LcrV antigen, capsule protein fraction 1, type III secretion system needle tip protein). The protein is produced as an N-terminal GST fusion, with GST being cleaved by thrombin and is not present in the final product. |
Canine Herpes Virus Antigen |
|
NAT41592-100 |
The Native Antigen Company |
0.1 |
EUR 395.28 |
|
|
|
Description: Canine Herpes virus, produced in MDCK cells. |
Canine Adenovirus 1 Antigen |
|
NAT41587-100 |
The Native Antigen Company |
0.1 |
EUR 395.28 |
|
|
|
Description: Canine Adenovirus Type 1, produced in A-72 cells. |
Canine Adenovirus 2 Antigen |
|
NAT41588-100 |
The Native Antigen Company |
0.1 |
EUR 395.28 |
|
|
|
Description: Canine Adenovirus Type 2, produced in A-72 cells. |
Toxoplasma gondii IgM antigen |
|
TG-IgM-100 |
The Native Antigen Company |
0.1mg |
EUR 139.86 |
|
Description: A highly purified source of Toxoplasma gondii membrane antigens, optimised for IgM detection. |
Toxoplasma gondii IgM antigen |
|
TG-IgM-1000 |
The Native Antigen Company |
1.0mg |
EUR 1189.51 |
|
Description: A highly purified source of Toxoplasma gondii membrane antigens, optimised for IgM detection. |
Canine Distemper Virus Antigen |
|
NAT41591-100 |
The Native Antigen Company |
0.1 |
EUR 395.28 |
|
|
|
Description: Canine Distemper virus, produced in SL-29 cells. |
Norovirus GII.4 VP1 Antigen |
|
REC31620-100 |
The Native Antigen Company |
0.1 |
EUR 305.15 |
|
|
|
Description: Recombinant Norovirus GII.4 VP1 antigen produced in 293 human cells. |
Norovirus GII.4 VP1 Antigen |
|
REC31620-1000 |
The Native Antigen Company |
1.0 |
EUR 1847.65 |
|
|
|
Description: Recombinant Norovirus GII.4 VP1 antigen produced in 293 human cells. |
Norovirus GII.4 VP1 Antigen |
|
REC31620-500 |
The Native Antigen Company |
0.5 |
EUR 1076.4 |
|
|
|
Description: Recombinant Norovirus GII.4 VP1 antigen produced in 293 human cells. |
Canine Parainfluenza Virus Antigen |
|
NAT41593-100 |
The Native Antigen Company |
0.1 |
EUR 395.28 |
|
|
|
Description: Canine Parainfluenza virus antigen, produced in MDCK cells. |
Feline Panleukopenia Virus Antigen |
|
NAT41597-100 |
The Native Antigen Company |
0.1 |
EUR 395.28 |
|
|
|
Description: Feline Panleukopenia Virus (FPLV; feline parvovirus) antigen, produced in CRFK cells. |
Cytomegalovirus Cell Lysate Antigen |
|
CMV-CL-100 |
The Native Antigen Company |
0.1 |
EUR 225.32 |
|
|
|
Description: A clarified cell lysate containing a mix of CMV antigens from all stages of the replication life cycle. |
Cytomegalovirus Cell Lysate Antigen |
|
CMV-CL-1000 |
The Native Antigen Company |
1.0 |
EUR 1435.63 |
|
|
|
Description: A clarified cell lysate containing a mix of CMV antigens from all stages of the replication life cycle. |
Feline Viral Rhinotracheitis Antigen |
|
NAT41598-100 |
The Native Antigen Company |
0.1 |
EUR 395.28 |
|
|
|
Description: Feline Viral Rhinotracheitis (FVR; feline herpes virus, FHV-1) antigen, produced in CRFK cells. |
Herpes Simplex Virus 1 Antigen |
|
HS105-1000 |
The Native Antigen Company |
1.0 |
EUR 1189.71 |
|
|
|
Description: HSV-1 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
Herpes Simplex Virus 1 Antigen |
|
HS105-200 |
The Native Antigen Company |
0.2 |
EUR 297.43 |
|
|
|
Description: HSV-1 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
Herpes Simplex Virus 2 Antigen |
|
HS205-1000 |
The Native Antigen Company |
1.0 |
EUR 1189.71 |
|
|
|
Description: HSV-2 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
Herpes Simplex Virus 2 Antigen |
|
HS205-200 |
The Native Antigen Company |
0.2 |
EUR 297.43 |
|
|
|
Description: HSV-2 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
Ross River Virus Recombinant Antigen |
|
REC31969-100 |
The Native Antigen Company |
0.1 |
EUR 764.81 |
|
|
|
Description: Recombinant Ross River virus antigen expressed in HEK293 cells as virus-like particles and purified by sucrose density gradients and precipitation. Virus-like particles were then solubilized in PBS containing 0.2% SDS to prevent aggregation of particles. The preparation is not particulate. Antigens in the preparation include Envelope proteins 1 and 2 and Nucleoprotein. |
Ross River Virus Recombinant Antigen |
|
REC31969-500 |
The Native Antigen Company |
0.5 |
EUR 2871.26 |
|
|
|
Description: Recombinant Ross River virus antigen expressed in HEK293 cells as virus-like particles and purified by sucrose density gradients and precipitation. Virus-like particles were then solubilized in PBS containing 0.2% SDS to prevent aggregation of particles. The preparation is not particulate. Antigens in the preparation include Envelope proteins 1 and 2 and Nucleoprotein. |
Canine Adenovirus 1 and 2 Antigen |
|
NAT41589-100 |
The Native Antigen Company |
0.1 |
EUR 395.28 |
|
|
|
Description: A mixture of Canine Adenovirus Type 1 and Type 2, produced in A-72 cells. |
Hepatitis B Virus E Antigen (HBeAg) |
|
REC31677-100 |
The Native Antigen Company |
0.1 |
EUR 460.95 |
|
|
|
Description: Recombinant Hepititis B Virus E Protein (HBeAg). |
Hepatitis B Virus E Antigen (HBeAg) |
|
REC31677-500 |
The Native Antigen Company |
0.5 |
EUR 1382.84 |
|
|
|
Description: Recombinant Hepititis B Virus E Protein (HBeAg). |
Hepatitis B Virus Core Antigen (HBcAg) |
|
REC31689-100 |
The Native Antigen Company |
0.1 |
EUR 460.95 |
|
|
|
Description: Recombinant Hepititis B Virus Core Protein (HBcAg). |
Hepatitis B Virus Core Antigen (HBcAg) |
|
REC31689-500 |
The Native Antigen Company |
0.5 |
EUR 1382.84 |
|
|
|
Description: Recombinant Hepititis B Virus Core Protein (HBcAg). |
Hepatitis C Virus Core Antigen (HCcAg) |
|
REC31693-100 |
The Native Antigen Company |
0.1 |
EUR 489.27 |
|
|
|
Description: Recombinant Hepatitis C Virus core protein is produced in E. coli and fused with a His-tag. |
Hepatitis C Virus Core Antigen (HCcAg) |
|
REC31693-500 |
The Native Antigen Company |
0.5 |
EUR 1469.11 |
|
|
|
Description: Recombinant Hepatitis C Virus core protein is produced in E. coli and fused with a His-tag. |
Feline Infectious Peritonitis Virus Antigen |
|
NAT41596-100 |
The Native Antigen Company |
0.1 |
EUR 395.28 |
|
|
|
Description: Feline Infectious Peritonitis virus (FIPV; feline coronavirus) antigen, produced in CRFK cells. |
Herpes Simplex Virus 1 Lysate Antigen |
|
HS104-1000 |
The Native Antigen Company |
1.0 |
EUR 272.96 |
|
|
|
Description: A high concentration of HSV-1 particles and proteins from a clarified cell lysate. |
Herpes Simplex Virus 2 Lysate Antigen |
|
HS204-1000 |
The Native Antigen Company |
1.0 |
EUR 272.96 |
|
|
|
Description: A high concentration of HSV-2 particles and proteins from a clarified cell lysate. |
Toxoplasma gondii IgG antigen, RH strain |
|
TG-IgG-1000 |
The Native Antigen Company |
1.0 mg |
EUR 338 |
|
Description: A concentrated source of Toxoplasma gondii tachyzoite antigens, optimised for IgG detection, diluted to 0.5 mg/ml. |
Toxoplasma gondii IgG antigen, RH strain |
|
TG-IgG-200 |
The Native Antigen Company |
0.2 mg |
EUR 174.83 |
|
Description: A concentrated source of Toxoplasma gondii tachyzoite antigens, optimised for IgG detection, diluted to 0.5 mg/ml. |
Toxoplasma gondii IgG antigen, RH strain |
|
TG-IgG-5000 |
The Native Antigen Company |
5.0 mg |
EUR 1436.48 |
|
Description: A concentrated source of Toxoplasma gondii tachyzoite antigens, optimised for IgG detection, diluted to 0.5 mg/ml. |
Legionella pneumophila antigen (native extract) |
|
NAT41580-100 |
The Native Antigen Company |
0.1 |
EUR 395.28 |
|
|
|
Description: Inactivated Legionella pneumophila antigen from culture. |
Streptococcus Pneumoniae Antigen, Native Extract |
|
NAT41604-100 |
The Native Antigen Company |
0.1 |
EUR 395.28 |
|
|
|
Description: Inactivated Streptococcus pneumoniae antigen from culture. |
Leptospira Biflexa Antigen (Strain Patoc 1) |
|
NAT41582-100 |
The Native Antigen Company |
0.1 |
EUR 395.28 |
|
|
|
Description: Inactivated Leptospira biflexa antigen (Strain Patoc 1) from broth culture. |
Leptospira Biflexa Antigen (Strain Patoc 1) |
|
NAT41582-500 |
The Native Antigen Company |
0.5 |
EUR 1187.13 |
|
|
|
Description: Inactivated Leptospira biflexa antigen (Strain Patoc 1) from broth culture. |
Scl-70 ELISA |
|
E22-HC9088 |
EnoGene |
96T |
EUR 495 |
|
|
Scl-70 ELISA |
|
MBS8579308-5x96Tests |
MyBiosource |
5x96Tests |
EUR 2735 |
Scl-70 ELISA |
|
MBS8579308-96Tests |
MyBiosource |
96Tests |
EUR 595 |
Mouse Anti-Hepatitis B Surface Antigen Antibody (1834) |
|
MAB12230-100 |
The Native Antigen Company |
0.1 |
EUR 278.11 |
|
|
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus surface antigen (1834). |
Mouse Anti-Hepatitis B Surface Antigen Antibody (1837) |
|
MAB12231-100 |
The Native Antigen Company |
0.1 |
EUR 278.11 |
|
|
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus surface antigen (1837) |
Mouse Anti-Hepatitis B Surface Antigen Antibody (1838) |
|
MAB12232-100 |
The Native Antigen Company |
0.1 |
EUR 278.11 |
|
|
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus surface antigen (1838) |
Mouse Anti-Hepatitis B Virus E Antigen Antibody (1892) |
|
MAB12226-100 |
The Native Antigen Company |
0.1 |
EUR 198.28 |
|
|
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (1892) |
Mouse Anti-Hepatitis B Virus E Antigen Antibody (1893) |
|
MAB12227-100 |
The Native Antigen Company |
0.1 |
EUR 278.11 |
|
|
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (1893) |
Mouse Anti-Hepatitis B Virus E Antigen Antibody (1894) |
|
MAB12228-100 |
The Native Antigen Company |
0.1 |
EUR 278.11 |
|
|
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (1894) |
Mouse Anti-Hepatitis B Virus E Antigen Antibody (M132) |
|
MAB12298-100 |
The Native Antigen Company |
0.1 |
EUR 279.4 |
|
|
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M132) |
Mouse Anti-Hepatitis B Virus E Antigen Antibody (M132) |
|
MAB12298-500 |
The Native Antigen Company |
0.5 |
EUR 701.72 |
|
|
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M132) |
Mouse Anti-Hepatitis B Virus E Antigen Antibody (M133) |
|
MAB12299-100 |
The Native Antigen Company |
0.1 |
EUR 279.4 |
|
|
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M133) |
Mouse Anti-Hepatitis B Virus E Antigen Antibody (M133) |
|
MAB12299-500 |
The Native Antigen Company |
0.5 |
EUR 701.72 |
|
|
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M133) |
Zika Virus Envelope Protein, Suriname Strain (SCL) |
|
REC31998-100 |
The Native Antigen Company |
0.1 |
EUR 730.05 |
|
|
|
Description: Recombinant Zika virus envelope protein expressed in HEK293 mammalian cells, with C terminal 6-His tag. |
Zika Virus Envelope Protein, Suriname Strain (SCL) |
|
REC31998-250 |
The Native Antigen Company |
0.25 |
EUR 1505.16 |
|
|
|
Description: Recombinant Zika virus envelope protein expressed in HEK293 mammalian cells, with C terminal 6-His tag. |
Yersinia pestis chain B F1 capsule antigen, C-terminal His-tag |
|
REC32027-100 |
The Native Antigen Company |
0.1 |
EUR 326.34 |
|
Description: Yersinia pestis chain B F1 capsule antigen (Antig_Caf1) |
Yersinia pestis chain B F1 capsule antigen, C-terminal His-tag |
|
REC32027-500 |
The Native Antigen Company |
0.5 |
EUR 1386.95 |
|
Description: Yersinia pestis chain B F1 capsule antigen (Antig_Caf1) |
Scl-70 ELISA Kit |
|
MBS580083-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 1150 |
Scl-70 ELISA Kit |
|
MBS580083-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 265 |
recombinant human Scl-70 |
|
E4A10X29 |
EnoGene |
100ug |
EUR 595 |
Recombinant human Scl-70 |
|
A10X29 |
BioNC |
1 Each |
Ask for price |
Rat Scl-70 Antibody ELISA Kit |
|
MBS046525-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 6725 |
Rat Scl-70 Antibody ELISA Kit |
|
MBS046525-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 550 |
Rat Scl-70 Antibody ELISA Kit |
|
MBS046525-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3420 |
Rat Scl-70 Antibody ELISA Kit |
|
MBS046525-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 765 |
Cat Scl-70 Antibody ELISA Kit |
|
MBS098851-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
Rat Scl-70 Antibody ELISA Kit |
|
MBS733766-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 5685 |
Rat Scl-70 Antibody ELISA Kit |
|
MBS733766-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 485 |
Rat Scl-70 Antibody ELISA Kit |
|
MBS733766-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3020 |
Rat Scl-70 Antibody ELISA Kit |
|
MBS733766-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 690 |
Duck Scl-70 Antibody ELISA Kit |
|
MBS064027-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
Cavy Scl-70 Antibody ELISA Kit |
|
MBS042029-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
Fish Scl-70 Antibody ELISA Kit |
|
MBS044490-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
Goat Scl-70 Antibody ELISA Kit |
|
MBS005211-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
Goat Scl-70 Antibody ELISA Kit |
|
MBS745982-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 5685 |
Goat Scl-70 Antibody ELISA Kit |
|
MBS745982-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 485 |
Goat Scl-70 Antibody ELISA Kit |
|
MBS745982-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3020 |
Goat Scl-70 Antibody ELISA Kit |
|
MBS745982-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 690 |
Camel Scl-70 Antibody ELISA Kit |
|
MBS077184-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
Sheep Scl-70 Antibody ELISA Kit |
|
MBS035116-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 6725 |
Sheep Scl-70 Antibody ELISA Kit |
|
MBS035116-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 550 |
Sheep Scl-70 Antibody ELISA Kit |
|
MBS035116-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3420 |
Sheep Scl-70 Antibody ELISA Kit |
|
MBS035116-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 765 |
Mouse Scl-70 Antibody ELISA Kit |
|
MBS035621-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 6725 |
Mouse Scl-70 Antibody ELISA Kit |
|
MBS035621-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 550 |
Mouse Scl-70 Antibody ELISA Kit |
|
MBS035621-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3420 |
Our information recommend that epoxiconazole acts primarily by lowering ldl cholesterol biosynthesis within the cells. We conclude that epoxiconazole bears the potential to hurt human embryonic improvement via inhibition of the steroid biosynthesis pathway. As this can be a standard characteristic of compounds that concentrate on sterol 14α-demethylase, we add proof to the belief that conazole fungicides could also be human developmental toxicants.